Anti-pigmentation Activity of UAS Dermqure Eventone Complex

An open label Clinical Study to Evaluate the Anti-pigmentation Activity of UAS Dermqure Eventone Complex - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/04/108415

Enrollment

Registered

2026-04-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dermqure Eventone Complex: Test Product: Dermqure Eventone Complex Dose: 1.5 gm twice a day Route of Administration: Topical Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Male or Female with age 25-55. 2. Fitzpatrick skin type III VI (preferred) 3. Subjects having uneven tone / hyperpigmentation (Mild to Moderate) 4. Subject willing to give written informed consent 5. Subjects willing to avoid conflicting skincare products. 6. Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 7. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2. Volunteers with skin conditions such as eczema, psoriasis 3. Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 4. Have open sore or open lesions in the treatment area 5. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 6. Subjects participated in Recent aesthetic procedure (less than 12 weeks) 7. Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 8. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 9. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years. 10. Subjects have use any prescription retinoids or depigmenting drugs within 4 weeks.

Design outcomes

Primary

Measure	Time frame
1. Change in Dark spots 2. Change in Pigmentation 3. Change in skin hydration 4. Change in TEWL (for barrier function) 5. Change in Gloss 6. Dermatological EvaluationTimepoint: Day0, Day28, Day56, Day84	—

Secondary

Measure	Time frame
1. HD ImagingTimepoint: Day0, Day84	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results